NEW SOLID FORMS OF CANNABIDIOL AND USES THEREOF
Disclosed herein are cocrystals of cannabidiol and a coformer containing 5-6 membered rings comprised of carbon and nitrogen atoms, wherein the 5-6 membered rings can be unsaturated or saturated and the rings contain 1 to 2 nitrogen atoms. Cocrystals of cannabidiol and a coformer selected from L-proline, D-proline, tetramethylpyrazine, and 4,4′-dipyridyl are also disclosed herein
1 . A solid form comprising cannabidiol and the coformer L-proline.
2 . The solid form of claim 1 having an x-ray diffraction pattern (XRPD) comprising one or more peaks at 5.3, 5.8, 9.4, 10.7, 11.1, 11.4, 11.7, 12.3, 15.4, 15.8, 16.4, 17.3, 18.7, 19.2, 19.4, 20.0, 20.8, 21.3, 23.1, and 24.5 degrees 2θ±0.2.
3 . The solid form of claim 3 having an x-ray powder diffraction pattern substantially similar to FIG. 2 .
4 . The solid form of claim 1 wherein the molar ratio of cannabidiol to L-proline is about 1:1.
5 . The solid form of claim 1 , which is crystalline.
6 . The solid form of claim 1 , which is a cocrystal.
7 . The solid form of claim 6 , wherein the cocrystal is anhydrous.
8 . The solid form of claim 1 having a DSC thermogram with a peak onset of about 146.4° C. or a peak maximum at about 147.8° C.
9 . The solid form of claim 8 having a DSC thermogram which is substantially similar to the DSC thermogram of FIG. 3 .
10 . A pharmaceutical composition comprising the solid form of claim 1 .
11 . The pharmaceutical composition of claim 10 , further comprising a pharmaceutically acceptable excipient or carrier.
12 . A solid form comprising cannabidiol and the coformer D-proline.
13 . The solid form of claim 12 having an x-ray diffraction pattern comprising one or more peaks at 5.2, 5.8, 9.4, 10.6, 11.2, 11.5, 12.4, 12.7, 15.3, 15.7, 16.4, 17.4, 18.7, 19.2, 19.4, 20.2, 20.7, 21.2, 23.3, 24.0, 24.6, 25.6, and 26.2 degrees 2θ±0.2.
14 . The solid form of claim 13 having an x-ray powder diffraction pattern substantially similar to FIG. 7 .
15 . The solid form of claim 12 wherein the molar ratio of cannabidiol to D-proline is about 1:1.
16 . The solid form of claim 12 , which is crystalline.
17 . The solid form of claim 12 , which is a cocrystal.
18 . The solid form of claim 17 , wherein the cocrystal is anhydrous.
19 . The solid form of claim 12 having a DSC thermogram with a peak onset of about 154.3° C. or a peak maximum at about 155.5° C.
20 . The solid form of claim 19 having a DSC thermogram which is substantially similar to the DSC thermogram of FIG. 8
21 . A pharmaceutical composition comprising the solid form of claim 12 .
22 . The pharmaceutical composition of claim 21 , further comprising a pharmaceutically acceptable excipient or carrier.
23 . A solid form comprising cannabidiol and the coformer tetramethylpyrazine.
24 . The solid form of claim 23 having an x-ray diffraction pattern comprising one or more peaks at about 9.1, 14.6, 18.3, and 19.6 degrees 2θ±0.2.
25 . The solid form of claim 24 having an x-ray powder diffraction pattern substantially similar to FIG. 12 .
26 . The solid form of claim 23 , wherein the molar ratio of cannabidiol to tetramethylpyrazine is about 1:1.
27 . The solid form of claim 23 , which is crystalline.
28 . The solid form of claim 23 , which is a cocrystal.
29 . The solid form of claim 23 having a DSC thermogram with a peak onset of approximately 89.9° C. or a peak maximum at about 92.8° C.
30 . The solid form of claim 29 having a DSC thermogram which is substantially similar to the DSC thermogram of FIG. 13